{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:01Z","timestamp":1791908281729,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016477","name":"CareDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ekir.2025.103757","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:23:06Z","timestamp":1767140586000},"page":"103757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Metabolic Dysfunction\u2013Associated Steatotic Liver Disease\u2013CKD Axis: Intersecting Pathways and Opportunities for Early Intervention"],"prefix":"10.1016","volume":"11","author":[{"given":"Sriram","family":"Sriperumbuduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathab Balaji","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.103757_bib1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s42255-024-00985-1","article-title":"From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research","volume":"6","author":"Hsu","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.ekir.2025.103757_bib2","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103757_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.103757_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLOS Med"},{"key":"10.1016\/j.ekir.2025.103757_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.ekir.2025.103757_bib17","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.3390\/ijms23137007","article-title":"MAFLD and CKD: an updated narrative review","volume":"23","author":"Mantovani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2025.103757_bib8","article-title":"Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes","author":"Yeung","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ekir.2025.103757_bib9","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.1038\/s41598-020-65940-y","article-title":"Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease","volume":"10","author":"Chon","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.103757_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63386-0","article-title":"Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study","volume":"14","author":"Cen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.103757_bib11","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1038\/s41598-021-88025-w","article-title":"Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects","volume":"11","author":"Takahashi","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.103757_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21039-0","article-title":"Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men","volume":"12","author":"Kuma","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.103757_bib13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","article-title":"Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants","volume":"17","author":"Chen","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ekir.2025.103757_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.nefroe.2024.03.009","article-title":"Targeting metabolic-associated fatty liver disease in diabetic kidney disease: a call to action","volume":"44","author":"Benlloch","year":"2024","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.ekir.2025.103757_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/antiox11010091","article-title":"Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease","volume":"11","author":"Ma","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ekir.2025.103757_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ekir.2025.103757_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102814","article-title":"Utility of non-invasive liver fibrosis markers to predict the incidence of chronic kidney disease (CKD): a systematic review, meta-analysis, and meta-regression","volume":"17","author":"Supriyadi","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ekir.2025.103757_bib19","article-title":"Liver fibrosis progression analyzed with AI predicts renal decline","volume":"7","author":"Sun","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ekir.2025.103757_bib20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ekir.2025.103757_bib21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103757_bib22","unstructured":"Chronic kidney disease: assessment and management | Guidance | NICE. Accessed March 18, 2025. Recommendations. https:\/\/www.nice.org.uk\/guidance\/ng203\/chapter\/Recommendations#risk-assessment-referral-criteria-and-shared-care"},{"key":"10.1016\/j.ekir.2025.103757_bib23","article-title":"Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease","volume":"11","author":"Chen","year":"2024","journal-title":"Front Nutr"},{"key":"10.1016\/j.ekir.2025.103757_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ekir.2025.103757_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3350\/cmh.2020.0067","article-title":"Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH","volume":"26","author":"Hydes","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ekir.2025.103757_bib26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/heartjnl-2022-321930","article-title":"Primary prevention of cardiovascular disease in women with a Mediterranean diet: systematic review and meta-analysis","volume":"109","author":"Pant","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.ekir.2025.103757_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1463502","article-title":"Safety and impact of the Mediterranean diet in patients with chronic kidney disease: a pilot randomized crossover trial","volume":"11","author":"Kwon","year":"2024","journal-title":"Front Nutr"},{"issue":"3 Suppl 1","key":"10.1016\/j.ekir.2025.103757_bib28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.103757_bib29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/nutrit\/nuz029","article-title":"Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review","volume":"77","author":"Reddy","year":"2019","journal-title":"Nutr Rev"},{"key":"10.1016\/j.ekir.2025.103757_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00535-021-01833-9","article-title":"Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review","volume":"56","author":"Kamada","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ekir.2025.103757_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/nu12041007","article-title":"Ameliorating chronic kidney disease using a whole food plant-based diet","volume":"12","author":"Adair","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ekir.2025.103757_bib32","article-title":"Optimizing diet to slow CKD progression","volume":"8","author":"Molina","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2025.103757_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ekir.2025.103757_bib34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12882-019-1586-5","article-title":"Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.103757_bib35","article-title":"Altered dietary salt intake for people with chronic kidney disease","volume":"6","author":"McMahon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2025.103757_bib36","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1681\/ASN.2020010028","article-title":"The effects of high-protein diets on kidney health and longevity","volume":"31","author":"Ko","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103757_bib37","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2147\/IJGM.S460200","article-title":"Evaluation of MASLD fibrosis, FIB-4 and Apri score in MASLD combined with T2DM and MACCEs receiving SGLT2 inhibitors treatment","volume":"17","author":"Liu","year":"2024","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.ekir.2025.103757_bib38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00535-024-02122-x","article-title":"Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ekir.2025.103757_bib39","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.103757_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.ekir.2025.103757_bib41","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ekir.2025.103757_bib42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ekir.2025.103757_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031280","article-title":"De novo lipogenesis in adipose tissue is associated with course of morbid obesity after bariatric surgery","volume":"7","author":"Garrido-S\u00e1nchez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.103757_bib44","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1073\/pnas.161284298","article-title":"A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver","volume":"98","author":"Yamashita","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2025.103757_bib45","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.cmet.2024.10.009","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8 T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2025.103757_bib46","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib47","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.103757_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis","author":"Neuen","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2025.103757_bib50","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/dc24-2169","article-title":"Risk of urogenital infections in people with type 2 diabetes initiating SGLT2is versus GLP-1RAs in routine clinical care: a Danish cohort study","volume":"48","author":"Ljungberg","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.103757_bib51","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2025.103757_bib52","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.103757_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.103757_bib55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.103757_bib56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist Retatrutide for obesity - A Phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib57","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.103757_bib59","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2025.103757_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib60","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.ekir.2025.103757_bib61","doi-asserted-by":"crossref","first-page":"E1415","DOI":"10.1152\/ajpendo.00419.2013","article-title":"Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet","volume":"305","author":"Wada","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ekir.2025.103757_bib62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103757_bib63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.103757_bib64","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib65","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib66","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.103757_bib67","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.043373","article-title":"Nonsteroidal versus steroidal mineralocorticoid receptor antagonists in heart failure: real-world evidence from a multicenter cohort study","volume":"14","author":"Wu","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2025.103757_bib68","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib69","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/biom15030324","article-title":"Linking cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD): the role of cardiometabolic drugs in MASLD treatment","volume":"15","author":"Zisis","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ekir.2025.103757_bib70","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ekir.2025.103757_bib71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.103757_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11906-017-0771-9","article-title":"Effects of RAAS inhibitors in patients with kidney disease","volume":"19","author":"Zhang","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ekir.2025.103757_bib73","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12882-017-0753-9","article-title":"Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients","volume":"18","author":"Vejakama","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.103757_bib74","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/M23-3236","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: s systematic review and retrospective individual participant-level meta-analysis of clinical trials","volume":"177","author":"Ku","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2025.103757_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.824095","article-title":"RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study","volume":"9","author":"Riccio","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2025.103757_bib76","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.103757_bib77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41366-020-00707-z","article-title":"Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects study","volume":"45","author":"Shulman","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.ekir.2025.103757_bib78","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/s41366-018-0045-x","article-title":"Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study","volume":"42","author":"Shulman","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.ekir.2025.103757_bib83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eng.2024.03.019","article-title":"Manipulating the gut microbiome to alleviate steatotic liver disease: current progress and challenges","volume":"40","author":"Saenz","year":"2024","journal-title":"Engineering"},{"key":"10.1016\/j.ekir.2025.103757_bib80","article-title":"The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl","key":"10.1016\/j.ekir.2025.103757_bib81","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Saeed","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ekir.2025.103757_bib84","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1080\/10408398.2018.1458021","article-title":"Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD","volume":"59","author":"Hadi","year":"2019","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.ekir.2025.103757_bib85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/diagnostics15010021","article-title":"The gut\u2013kidney axis in chronic kidney diseases","volume":"15","author":"Tsuji","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ekir.2025.103757_bib79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MNH.0000000000000661","article-title":"Microbiome modulation as a novel therapeutic approach in chronic kidney disease","volume":"30","author":"Sumida","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2025.103757_bib82","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1053\/j.jrn.2022.12.004","article-title":"Targeting the gut microbiota in kidney disease: the future in renal nutrition and metabolism","volume":"33","author":"Lambert","year":"2023","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.ekir.2025.103757_bib86","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103757_bib87","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/cimb47030154","article-title":"Drug pipeline for MASLD: what can be learned from the successful story of resmetirom","volume":"47","author":"Knezovi\u0107","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.ekir.2025.103757_bib88","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cpt.3606","article-title":"Insights into clinical trials for drugs targeting MASLD: progress, challenges, and future directions","volume":"117","author":"Wu","year":"2025","journal-title":"Clin Pharmacol Ther"}],"updated-by":[{"DOI":"10.1016\/j.ekir.2026.106587","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000}},{"DOI":"10.1016\/j.ekir.2026.106587","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:24:42Z","timestamp":1775265882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925007752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2468024925007752"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103757","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Metabolic Dysfunction\u2013Associated Steatotic Liver Disease\u2013CKD Axis: Intersecting Pathways and Opportunities for Early Intervention","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103757"}}